Cluster	ID	Description	GeneRatio	BgRatio	pvalue	p.adjust	qvalue	geneID	Count
group_G5_1_0	hsa04140	Autophagy - animal	18/45	141/8158	7.22397224191493e-21	1.2569711700932e-18	3.04167252291155e-19	HRAS/BECN1/TSC1/ATG4A/ATG2A/PRKAA1/ATG13/RAB7A/PIK3CB/RB1CC1/ZFYVE1/MAP1LC3A/MAPK3/STK11/AMBRA1/BCL2L1/ATG14/ATG12	18
group_G5_1_0	hsa04137	Mitophagy - animal	12/45	72/8158	1.9598942837172e-15	1.70510802683396e-13	4.12609322887832e-14	TFEB/TFE3/HRAS/OPTN/BECN1/MFN2/RELA/RAB7A/MAP1LC3A/SRC/AMBRA1/BCL2L1	12
group_G5_1_0	hsa05022	Pathways of neurodegeneration - multiple diseases	18/45	476/8158	1.76934743675988e-11	1.02622151332073e-09	2.48329464808404e-10	HRAS/OPTN/BECN1/MFN2/RELA/ATG2A/ATG13/PSEN1/RB1CC1/ZFYVE1/MAP1LC3A/MAPK3/MAPK14/AMBRA1/NFKB1/HTRA2/BCL2L1/ATG14	18
group_G5_1_0	hsa05167	Kaposi sarcoma-associated herpesvirus infection	12/45	194/8158	3.36957270101098e-10	1.46576412493977e-08	3.54691863264313e-09	HRAS/BECN1/RELA/PIK3CB/MAP1LC3A/MAPK3/MAPK14/SRC/STAT1/NFKB1/IKBKB/ATG14	12
group_G5_1_0	hsa04211	Longevity regulating pathway	9/45	89/8158	9.31842634107836e-10	3.24281236669527e-08	7.84709586617125e-09	HRAS/TSC1/RELA/PRKAA1/ATG13/PIK3CB/RB1CC1/STK11/NFKB1	9
group_G5_1_0	hsa04917	Prolactin signaling pathway	8/45	70/8158	3.26444314828881e-09	9.42786418631275e-08	2.28139484242293e-08	HRAS/RELA/PIK3CB/MAPK3/MAPK14/SRC/STAT1/NFKB1	8
group_G5_1_0	hsa04625	C-type lectin receptor signaling pathway	9/45	104/8158	3.79281892552812e-09	9.42786418631275e-08	2.28139484242293e-08	HRAS/RELA/PIK3CB/MAPK3/MAPK14/SRC/STAT1/NFKB1/IKBKB	9
group_G5_1_0	hsa05131	Shigellosis	12/45	247/8158	5.38647206408455e-09	1.17155767393839e-07	2.8349852968866e-08	BECN1/RELA/PIK3CB/MAP1LC3A/MAPK3/MAPK14/SRC/NFKB1/IKBKB/BCL2L1/ATG14/ATG12	12
group_G5_1_0	hsa05235	PD-L1 expression and PD-1 checkpoint pathway in cancer	8/45	89/8158	2.26087370009702e-08	4.37102248685424e-07	1.05771869010387e-07	HRAS/RELA/PIK3CB/MAPK3/MAPK14/STAT1/NFKB1/IKBKB	8
group_G5_1_0	hsa04068	FoxO signaling pathway	9/45	131/8158	2.92835302353116e-08	5.09533426094421e-07	1.23299074674996e-07	HRAS/SGK1/PRKAA1/PIK3CB/MAPK3/MAPK14/STK11/IKBKB/ATG12	9
group_G5_1_0	hsa04210	Apoptosis	9/45	136/8158	4.06340115112221e-08	6.22498173338261e-07	1.50634766688024e-07	HRAS/RELA/PMAIP1/PIK3CB/MAPK3/NFKB1/HTRA2/IKBKB/BCL2L1	9
group_G5_1_0	hsa04621	NOD-like receptor signaling pathway	10/45	184/8158	4.29309085060869e-08	6.22498173338261e-07	1.50634766688024e-07	MFN2/RELA/MAP1LC3A/MAPK3/MAPK14/STAT1/NFKB1/IKBKB/BCL2L1/ATG12	10
group_G5_1_0	hsa05221	Acute myeloid leukemia	7/45	67/8158	6.48663292754981e-08	8.65151063121189e-07	2.09352949333621e-07	HRAS/RELA/PIK3CB/PIM2/MAPK3/NFKB1/IKBKB	7
group_G5_1_0	hsa05132	Salmonella infection	11/45	249/8158	6.9609855653429e-08	8.65151063121189e-07	2.09352949333621e-07	HRAS/RAB5C/RELA/RAB7A/PIK3CB/MAPK3/MAPK14/NFKB1/VPS16/VPS11/IKBKB	11
group_G5_1_0	hsa05010	Alzheimer disease	13/45	384/8158	8.4070137947018e-08	9.75213600185408e-07	2.3598635213198e-07	HRAS/BECN1/RELA/ATG2A/ATG13/PSEN1/PIK3CB/RB1CC1/MAPK3/AMBRA1/NFKB1/IKBKB/ATG14	13
group_G5_1_0	hsa04150	mTOR signaling pathway	9/45	156/8158	1.33526790435573e-07	1.45210384598685e-06	3.51386290619928e-07	HRAS/SGK1/TSC1/PRKAA1/PIK3CB/MAPK3/RICTOR/STK11/IKBKB	9
group_G5_1_0	hsa05212	Pancreatic cancer	7/45	76/8158	1.57160516533155e-07	1.51921832648716e-06	3.67626939258842e-07	RELA/PIK3CB/MAPK3/STAT1/NFKB1/IKBKB/BCL2L1	7
group_G5_1_0	hsa05220	Chronic myeloid leukemia	7/45	76/8158	1.57160516533155e-07	1.51921832648716e-06	3.67626939258842e-07	HRAS/RELA/PIK3CB/MAPK3/NFKB1/IKBKB/BCL2L1	7
group_G5_1_0	hsa05161	Hepatitis B	9/45	162/8158	1.84689918592411e-07	1.69137083342524e-06	4.09285138154928e-07	HRAS/RELA/PIK3CB/MAPK3/MAPK14/SRC/STAT1/NFKB1/IKBKB	9
group_G5_1_0	hsa04722	Neurotrophin signaling pathway	8/45	119/8158	2.2222496467357e-07	1.93335719266006e-06	4.67842030891727e-07	HRAS/RELA/PSEN1/PIK3CB/MAPK3/MAPK14/NFKB1/IKBKB	8
group_G5_1_0	hsa05152	Tuberculosis	9/45	180/8158	4.53684005095243e-07	3.75909604221773e-06	9.09642115479184e-07	CEBPB/RAB5C/RELA/RAB7A/MAPK3/MAPK14/SRC/STAT1/NFKB1	9
group_G5_1_0	hsa04136	Autophagy - other	5/45	32/8158	7.32415136122162e-07	5.79273789478437e-06	1.40175145669313e-06	BECN1/ATG4A/ATG2A/ATG13/ATG12	5
group_G5_1_0	hsa04933	AGE-RAGE signaling pathway in diabetic complications	7/45	100/8158	1.04287670637593e-06	7.88958899606135e-06	1.90915644187812e-06	HRAS/RELA/PIK3CB/MAPK3/MAPK14/STAT1/NFKB1	7
group_G5_1_0	hsa04620	Toll-like receptor signaling pathway	7/45	104/8158	1.36145149112985e-06	9.47570237826375e-06	2.29297093242922e-06	RELA/PIK3CB/MAPK3/MAPK14/STAT1/NFKB1/IKBKB	7
group_G5_1_0	hsa04660	T cell receptor signaling pathway	7/45	104/8158	1.36145149112985e-06	9.47570237826375e-06	2.29297093242922e-06	HRAS/RELA/PIK3CB/MAPK3/MAPK14/NFKB1/IKBKB	7
group_G5_1_0	hsa05417	Lipid and atherosclerosis	9/45	215/8158	2.01590479205259e-06	1.34910551468135e-05	3.26462314502443e-06	HRAS/RELA/PIK3CB/MAPK3/MAPK14/SRC/NFKB1/IKBKB/BCL2L1	9
group_G5_1_0	hsa04668	TNF signaling pathway	7/45	112/8158	2.24678854360857e-06	1.39621859495676e-05	3.37862938888507e-06	CEBPB/RELA/PIK3CB/MAPK3/MAPK14/NFKB1/IKBKB	7
group_G5_1_0	hsa05145	Toxoplasmosis	7/45	112/8158	2.24678854360857e-06	1.39621859495676e-05	3.37862938888507e-06	RELA/MAPK3/MAPK14/STAT1/NFKB1/IKBKB/BCL2L1	7
group_G5_1_0	hsa04151	PI3K-Akt signaling pathway	11/45	354/8158	2.36347392641273e-06	1.41808435584764e-05	3.43154109098036e-06	HRAS/SGK1/TSC1/RELA/PRKAA1/PIK3CB/MAPK3/STK11/NFKB1/IKBKB/BCL2L1	11
group_G5_1_0	hsa05163	Human cytomegalovirus infection	9/45	225/8158	2.93719740724408e-06	1.70357449620157e-05	4.12238232595661e-06	HRAS/TSC1/RELA/PIK3CB/MAPK3/MAPK14/SRC/NFKB1/IKBKB	9
group_G5_1_0	hsa04662	B cell receptor signaling pathway	6/45	82/8158	5.10585101033345e-06	2.86586476063877e-05	6.93494194951912e-06	HRAS/RELA/PIK3CB/MAPK3/NFKB1/IKBKB	6
group_G5_1_0	hsa04380	Osteoclast differentiation	7/45	128/8158	5.48954692239323e-06	2.98494113905132e-05	7.22308805578057e-06	RELA/PIK3CB/MAPK3/MAPK14/STAT1/NFKB1/IKBKB	7
group_G5_1_0	hsa04926	Relaxin signaling pathway	7/45	129/8158	5.78072777947202e-06	3.04802010190343e-05	7.37572922420672e-06	HRAS/RELA/PIK3CB/MAPK3/MAPK14/SRC/NFKB1	7
group_G5_1_0	hsa04062	Chemokine signaling pathway	8/45	192/8158	8.31361333025565e-06	4.25461388077789e-05	1.02954963842175e-05	HRAS/RELA/PIK3CB/MAPK3/SRC/STAT1/NFKB1/IKBKB	8
group_G5_1_0	hsa05135	Yersinia infection	7/45	137/8158	8.60782595087003e-06	4.27931918700396e-05	1.03552793393925e-05	RELA/PIK3CB/MAPK3/MAPK14/SRC/NFKB1/IKBKB	7
group_G5_1_0	hsa05418	Fluid shear stress and atherosclerosis	7/45	139/8158	9.4705064754949e-06	4.57741146315587e-05	1.10766157608128e-05	RELA/PRKAA1/PIK3CB/MAPK14/SRC/NFKB1/IKBKB	7
group_G5_1_0	hsa04658	Th1 and Th2 cell differentiation	6/45	92/8158	9.97836684349305e-06	4.69252927234538e-05	1.13551827521969e-05	RELA/MAPK3/MAPK14/STAT1/NFKB1/IKBKB	6
group_G5_1_0	hsa04657	IL-17 signaling pathway	6/45	94/8158	1.13004006821932e-05	5.0916863847526e-05	1.23210801808895e-05	CEBPB/RELA/MAPK3/MAPK14/NFKB1/IKBKB	6
group_G5_1_0	hsa05017	Spinocerebellar ataxia	7/45	143/8158	1.14124005175489e-05	5.0916863847526e-05	1.23210801808895e-05	BECN1/ATG2A/ATG13/PIK3CB/RB1CC1/AMBRA1/ATG14	7
group_G5_1_0	hsa05215	Prostate cancer	6/45	97/8158	1.35464213897158e-05	5.89269330452636e-05	1.42593909365429e-05	HRAS/RELA/PIK3CB/MAPK3/NFKB1/IKBKB	6
group_G5_1_0	hsa04370	VEGF signaling pathway	5/45	59/8158	1.63028477182516e-05	6.91876951945312e-05	1.67423339853675e-05	HRAS/PIK3CB/MAPK3/MAPK14/SRC	5
group_G5_1_0	hsa05170	Human immunodeficiency virus 1 infection	8/45	212/8158	1.71669684197423e-05	7.11202977389324e-05	1.72099934032504e-05	HRAS/RELA/PIK3CB/MAPK3/MAPK14/NFKB1/IKBKB/BCL2L1	8
group_G5_1_0	hsa05142	Chagas disease	6/45	102/8158	1.80832686221476e-05	7.31741567500858e-05	1.77069949788471e-05	RELA/PIK3CB/MAPK3/MAPK14/NFKB1/IKBKB	6
group_G5_1_0	hsa04218	Cellular senescence	7/45	156/8158	2.01448453232635e-05	7.96637065056328e-05	1.92773639457067e-05	HRAS/TSC1/RELA/PIK3CB/MAPK3/MAPK14/NFKB1	7
group_G5_1_0	hsa05160	Hepatitis C	7/45	157/8158	2.09984251503767e-05	8.11939105814565e-05	1.96476492635103e-05	HRAS/RELA/PIK3CB/MAPK3/STAT1/NFKB1/IKBKB	7
group_G5_1_0	hsa05014	Amyotrophic lateral sclerosis	10/45	364/8158	2.17471784037275e-05	8.22610661358389e-05	1.99058841224051e-05	OPTN/BECN1/ATG2A/ATG13/RB1CC1/MAP1LC3A/MAPK14/AMBRA1/BCL2L1/ATG14	10
group_G5_1_0	hsa05208	Chemical carcinogenesis - reactive oxygen species	8/45	223/8158	2.47628869051333e-05	9.08821397386242e-05	2.19920483336054e-05	HRAS/RELA/PIK3CB/MAPK3/MAPK14/SRC/NFKB1/IKBKB	8
group_G5_1_0	hsa04659	Th17 cell differentiation	6/45	108/8158	2.50709351003101e-05	9.08821397386242e-05	2.19920483336054e-05	RELA/MAPK3/MAPK14/STAT1/NFKB1/IKBKB	6
group_G5_1_0	hsa04215	Apoptosis - multiple species	4/45	32/8158	2.59548394776905e-05	9.21661646758804e-05	2.23027621720219e-05	BECN1/PMAIP1/HTRA2/BCL2L1	4
group_G5_1_0	hsa04920	Adipocytokine signaling pathway	5/45	69/8158	3.51295519204028e-05	0.000119853765375492	2.90027260436762e-05	RELA/PRKAA1/STK11/NFKB1/IKBKB	5
group_G5_1_0	hsa05211	Renal cell carcinoma	5/45	69/8158	3.51295519204028e-05	0.000119853765375492	2.90027260436762e-05	TFE3/HRAS/PIK3CB/MAPK3/EPAS1	5
group_G5_1_0	hsa04014	Ras signaling pathway	8/45	235/8158	3.60930108597926e-05	0.000120772767107768	2.92251100079292e-05	HRAS/RAB5C/RELA/PIK3CB/MAPK3/NFKB1/IKBKB/BCL2L1	8
group_G5_1_0	hsa04622	RIG-I-like receptor signaling pathway	5/45	70/8158	3.76773162348507e-05	0.00012140468564563	2.93780243546594e-05	RELA/MAPK14/NFKB1/IKBKB/ATG12	5
group_G5_1_0	hsa05120	Epithelial cell signaling in Helicobacter pylori infection	5/45	70/8158	3.76773162348507e-05	0.00012140468564563	2.93780243546594e-05	RELA/MAPK14/SRC/NFKB1/IKBKB	5
group_G5_1_0	hsa04071	Sphingolipid signaling pathway	6/45	119/8158	4.34518399872956e-05	0.000137465821050717	3.32645664974512e-05	HRAS/RELA/PIK3CB/MAPK3/MAPK14/NFKB1	6
group_G5_1_0	hsa05140	Leishmaniasis	5/45	77/8158	5.97702528495534e-05	0.000185714714211112	4.49400397365063e-05	RELA/MAPK3/MAPK14/STAT1/NFKB1	5
group_G5_1_0	hsa05165	Human papillomavirus infection	9/45	331/8158	6.49765908377368e-05	0.000198349593083618	4.79974816899256e-05	HRAS/TSC1/RELA/PSEN1/PIK3CB/MAPK3/STAT1/NFKB1/IKBKB	9
group_G5_1_0	hsa01521	EGFR tyrosine kinase inhibitor resistance	5/45	79/8158	6.76235878211563e-05	0.000202870763463469	4.90915338084619e-05	HRAS/PIK3CB/MAPK3/SRC/BCL2L1	5
group_G5_1_0	hsa04910	Insulin signaling pathway	6/45	137/8158	9.55593276376832e-05	0.000281819034050117	6.81957735148497e-05	HRAS/TSC1/PRKAA1/PIK3CB/MAPK3/IKBKB	6
group_G5_1_0	hsa05162	Measles	6/45	139/8158	0.000103553591779156	0.000300305416159554	7.26691872134431e-05	RELA/PIK3CB/STAT1/NFKB1/IKBKB/BCL2L1	6
group_G5_1_0	hsa05203	Viral carcinogenesis	7/45	204/8158	0.000111694251972803	0.000318603276119143	7.7096981517034e-05	HRAS/RELA/PMAIP1/PIK3CB/MAPK3/SRC/NFKB1	7
group_G5_1_0	hsa05222	Small cell lung cancer	5/45	92/8158	0.000139913114142755	0.000392659384852248	9.50173950035688e-05	RELA/PIK3CB/NFKB1/IKBKB/BCL2L1	5
group_G5_1_0	hsa01522	Endocrine resistance	5/45	98/8158	0.000188528446889328	0.000506090900908818	0.000122466037727482	HRAS/PIK3CB/MAPK3/MAPK14/SRC	5
group_G5_1_0	hsa04932	Non-alcoholic fatty liver disease	6/45	155/8158	0.00018854587531736	0.000506090900908818	0.000122466037727482	RELA/PRKAA1/PIK3CB/MAPK14/NFKB1/IKBKB	6
group_G5_1_0	hsa05166	Human T-cell leukemia virus 1 infection	7/45	222/8158	0.0001890569457418	0.000506090900908818	0.000122466037727482	HRAS/RELA/PIK3CB/MAPK3/NFKB1/IKBKB/BCL2L1	7
group_G5_1_0	hsa05146	Amoebiasis	5/45	102/8158	0.000227475712871652	0.000599708697570719	0.000145120072007434	RAB5C/RELA/RAB7A/PIK3CB/NFKB1	5
group_G5_1_0	hsa05171	Coronavirus disease - COVID-19	7/45	232/8158	0.000247997827749968	0.000644054060126784	0.000155850952238786	RELA/PIK3CB/MAPK3/MAPK14/STAT1/NFKB1/IKBKB	7
group_G5_1_0	hsa04931	Insulin resistance	5/45	108/8158	0.000297052642838714	0.00076010529196965	0.000183933524977532	RELA/PRKAA1/PIK3CB/NFKB1/IKBKB	5
group_G5_1_0	hsa05164	Influenza A	6/45	171/8158	0.000321227100627935	0.000810050949409575	0.000196019588483866	RELA/PIK3CB/MAPK3/STAT1/NFKB1/IKBKB	6
group_G5_1_0	hsa04935	Growth hormone synthesis, secretion and action	5/45	119/8158	0.000465306141547234	0.00115661812327455	0.00027988339341187	HRAS/PIK3CB/MAPK3/MAPK14/STAT1	5
group_G5_1_0	hsa04919	Thyroid hormone signaling pathway	5/45	121/8158	0.000502341965957102	0.001229226319995	0.000297453434965517	HRAS/PIK3CB/MAPK3/SRC/STAT1	5
group_G5_1_0	hsa04664	Fc epsilon RI signaling pathway	4/45	68/8158	0.000508645373791033	0.001229226319995	0.000297453434965517	HRAS/PIK3CB/MAPK3/MAPK14	4
group_G5_1_0	hsa04613	Neutrophil extracellular trap formation	6/45	190/8158	0.000563979604003051	0.00134428015200727	0.000325294652633339	RELA/PIK3CB/MAPK3/MAPK14/SRC/NFKB1	6
group_G5_1_0	hsa01523	Antifolate resistance	3/45	30/8158	0.000573830645639095	0.0013492774640703	0.000326503923549983	RELA/NFKB1/IKBKB	3
group_G5_1_0	hsa01524	Platinum drug resistance	4/45	73/8158	0.000666309086384664	0.00154583708041242	0.000374068259022969	PMAIP1/PIK3CB/MAPK3/BCL2L1	4
group_G5_1_0	hsa05130	Pathogenic Escherichia coli infection	6/45	197/8158	0.000682748288977282	0.00156313424055325	0.000378253899710405	RELA/MAPK3/MAPK14/SRC/NFKB1/IKBKB	6
group_G5_1_0	hsa05133	Pertussis	4/45	76/8158	0.000776013133179845	0.00173746777867073	0.000420439873846516	RELA/MAPK3/MAPK14/NFKB1	4
group_G5_1_0	hsa05169	Epstein-Barr virus infection	6/45	202/8158	0.000778864866300671	0.00173746777867073	0.000420439873846516	RELA/PIK3CB/MAPK14/STAT1/NFKB1/IKBKB	6
group_G5_1_0	hsa04371	Apelin signaling pathway	5/45	139/8158	0.000943982346320073	0.00207915099062902	0.00050312183681283	HRAS/BECN1/PRKAA1/MAP1LC3A/MAPK3	5
group_G5_1_0	hsa05207	Chemical carcinogenesis - receptor activation	6/45	212/8158	0.00100237720869871	0.0021801704289197	0.000527566951946691	HRAS/RELA/PIK3CB/MAPK3/SRC/NFKB1	6
group_G5_1_0	hsa04936	Alcoholic liver disease	5/45	142/8158	0.00103916460932579	0.00223227953114429	0.00054017653506214	RELA/PRKAA1/MAPK14/NFKB1/IKBKB	5
group_G5_1_0	hsa04960	Aldosterone-regulated sodium reabsorption	3/45	37/8158	0.00106898530814481	0.0022683346782585	0.000548901313553176	SGK1/PIK3CB/MAPK3	3
group_G5_1_0	hsa04012	ErbB signaling pathway	4/45	85/8158	0.00118131176088451	0.0024764848963121	0.000599270392332026	HRAS/PIK3CB/MAPK3/SRC	4
group_G5_1_0	hsa05210	Colorectal cancer	4/45	86/8158	0.0012339832725397	0.00255610820740366	0.000618537981222907	HRAS/PMAIP1/PIK3CB/MAPK3	4
group_G5_1_0	hsa05219	Bladder cancer	3/45	41/8158	0.0014441907449021	0.00295634340721137	0.000715388604285872	HRAS/MAPK3/SRC	3
group_G5_1_0	hsa04912	GnRH signaling pathway	4/45	93/8158	0.00164973570852945	0.00333783736376889	0.00080770414126289	HRAS/MAPK3/MAPK14/SRC	4
group_G5_1_0	hsa05231	Choline metabolism in cancer	4/45	98/8158	0.00200060133184939	0.00398894500510477	0.000965261949208656	HRAS/TSC1/PIK3CB/MAPK3	4
group_G5_1_0	hsa04930	Type II diabetes mellitus	3/45	46/8158	0.00201739747384609	0.00398894500510477	0.000965261949208656	PIK3CB/MAPK3/IKBKB	3
group_G5_1_0	hsa04064	NF-kappa B signaling pathway	4/45	104/8158	0.00248619337664592	0.00486064772512798	0.0011762002964617	RELA/NFKB1/IKBKB/BCL2L1	4
group_G5_1_0	hsa04066	HIF-1 signaling pathway	4/45	109/8158	0.00294848798020365	0.0057004100950604	0.00137940958138183	RELA/PIK3CB/MAPK3/NFKB1	4
group_G5_1_0	hsa05213	Endometrial cancer	3/45	58/8158	0.00391611181404007	0.00748795006201068	0.00181196613720767	HRAS/PIK3CB/MAPK3	3
group_G5_1_0	hsa05202	Transcriptional misregulation in cancer	5/45	193/8158	0.00398914109077209	0.00754467988906895	0.00182569386305359	TFE3/CEBPB/RELA/NFKB1/BCL2L1	5
group_G5_1_0	hsa04152	AMPK signaling pathway	4/45	120/8158	0.00416644947644908	0.00779529256884021	0.001886338189677	TSC1/PRKAA1/PIK3CB/STK11	4
group_G5_1_0	hsa04611	Platelet activation	4/45	124/8158	0.00468279619800205	0.0086577316749231	0.00209503488806367	PIK3CB/MAPK3/MAPK14/SRC	4
group_G5_1_0	hsa04213	Longevity regulating pathway - multiple species	3/45	62/8158	0.00472692246619365	0.0086577316749231	0.00209503488806367	HRAS/PRKAA1/PIK3CB	3
group_G5_1_0	hsa04623	Cytosolic DNA-sensing pathway	3/45	63/8158	0.00494428968978093	0.00896152506272794	0.00216854810955304	RELA/NFKB1/IKBKB	3
group_G5_1_0	hsa05168	Herpes simplex virus 1 infection	8/45	495/8158	0.00511068984089842	0.0090302850737323	0.00218518695069142	TSC1/RELA/PIK3CB/SRC/STAT1/NFKB1/IKBKB/BCL2L1	8
group_G5_1_0	hsa05205	Proteoglycans in cancer	5/45	205/8158	0.00515180611993081	0.0090302850737323	0.00218518695069142	HRAS/PIK3CB/MAPK3/MAPK14/SRC	5
group_G5_1_0	hsa04929	GnRH secretion	3/45	64/8158	0.00516761894554	0.0090302850737323	0.00218518695069142	HRAS/PIK3CB/MAPK3	3
group_G5_1_0	hsa04010	MAPK signaling pathway	6/45	294/8158	0.00518981900789213	0.0090302850737323	0.00218518695069142	HRAS/RELA/MAPK3/MAPK14/NFKB1/IKBKB	6
group_G5_1_0	hsa05321	Inflammatory bowel disease	3/45	65/8158	0.00539695612623101	0.0092977263956851	0.00224990354402543	RELA/STAT1/NFKB1	3
group_G5_1_0	hsa04015	Rap1 signaling pathway	5/45	210/8158	0.00570100928641717	0.00972525113565282	0.00235335780657056	HRAS/PIK3CB/MAPK3/MAPK14/SRC	5
group_G5_1_1	hsa05110	Vibrio cholerae infection	7/10	50/8158	2.4837823520474e-14	4.22242999848058e-13	1.30725386949863e-13	ATP6V1F/ATP6V1G3/ATP6V0D1/ATP6V1B1/ATP6V0A4/ATP6AP1/ATP6V1G1	7
group_G5_1_1	hsa04966	Collecting duct acid secretion	6/10	27/8158	1.50769784576232e-13	1.28154316889797e-12	3.96762590990083e-13	ATP6V1F/ATP6V1G3/ATP6V0D1/ATP6V1B1/ATP6V0A4/ATP6V1G1	6
group_G5_1_1	hsa05120	Epithelial cell signaling in Helicobacter pylori infection	7/10	70/8158	2.96169537811413e-13	1.67829404759801e-12	5.195956803709e-13	ATP6V1F/ATP6V1G3/ATP6V0D1/ATP6V1B1/ATP6V0A4/ATP6AP1/ATP6V1G1	7
group_G5_1_1	hsa05323	Rheumatoid arthritis	7/10	93/8158	2.32314641712612e-12	9.873372272786e-12	3.05677160148173e-12	ATP6V1F/ATP6V1G3/ATP6V0D1/ATP6V1B1/ATP6V0A4/ATP6AP1/ATP6V1G1	7
group_G5_1_1	hsa00190	Oxidative phosphorylation	7/10	134/8158	3.17596335713347e-11	1.07982754142538e-10	3.34311932329839e-11	ATP6V1F/ATP6V1G3/ATP6V0D1/ATP6V1B1/ATP6V0A4/ATP6AP1/ATP6V1G1	7
group_G5_1_1	hsa04145	Phagosome	7/10	152/8158	7.77690618038727e-11	2.20345675110973e-10	6.8218475266555e-11	ATP6V1F/ATP6V1G3/ATP6V0D1/ATP6V1B1/ATP6V0A4/ATP6AP1/ATP6V1G1	7
group_G5_1_1	hsa04721	Synaptic vesicle cycle	6/10	78/8158	1.280354840895e-10	3.10943318503071e-10	9.62672812703006e-11	ATP6V1F/ATP6V1G3/ATP6V0D1/ATP6V1B1/ATP6V0A4/ATP6V1G1	6
group_G5_1_1	hsa04150	mTOR signaling pathway	6/10	156/8158	8.75785122519008e-09	1.86104338535289e-08	5.76174422709874e-09	LAMTOR1/ATP6V1F/FNIP2/ATP6V1G3/ATP6V1B1/ATP6V1G1	6
group_G5_1_1	hsa05165	Human papillomavirus infection	7/10	331/8158	1.83727160469239e-08	3.47040191997452e-08	1.0744278390014e-08	ATP6V1F/ATP6V1G3/ATP6V0D1/ATP6V1B1/ATP6V0A4/ATP6AP1/ATP6V1G1	7
group_G5_1_1	hsa04142	Lysosome	4/10	132/8158	1.27551858950149e-05	2.16838160215254e-05	6.71325573421839e-06	SLC11A2/ATP6V0D1/ATP6V0A4/ATP6AP1	4
group_G5_1_1	hsa05152	Tuberculosis	3/10	180/8158	0.00113082107298735	0.00174763256734408	0.000541062714348012	ATP6V0D1/ATP6V0A4/ATP6AP1	3
group_G5_1_2	hsa04142	Lysosome	6/8	132/8158	4.36780563731641e-10	3.05746394612149e-09	1.83907605781744e-09	CTSF/CLN5/MAN2B1/ACP5/GBA/GM2A	6
group_G5_1_2	hsa00511	Other glycan degradation	3/8	18/8158	5.01695676796683e-07	1.75593486878839e-06	1.05620142483512e-06	NEU4/MAN2B1/GBA	3
group_G5_1_2	hsa00600	Sphingolipid metabolism	2/8	53/8158	0.00113096582069322	0.00263892024828419	0.00158732045009575	NEU4/GBA	2
group_G5_2_1	hsa04966	Collecting duct acid secretion	7/12	27/8158	1.46200170528343e-15	2.0468023873968e-14	3.07789832691248e-15	ATP6V0E2/ATP6V1C2/ATP6V0D1/TCIRG1/ATP6V1B2/ATP6V1E1/ATP6V1G1	7
group_G5_2_1	hsa05110	Vibrio cholerae infection	7/12	50/8158	1.62419544373809e-13	1.13693681061666e-12	1.70967941446115e-13	ATP6V0E2/ATP6V1C2/ATP6V0D1/TCIRG1/ATP6V1B2/ATP6V1E1/ATP6V1G1	7
group_G5_2_1	hsa05120	Epithelial cell signaling in Helicobacter pylori infection	7/12	70/8158	1.92836886649373e-12	8.99905471030406e-12	1.35324130982016e-12	ATP6V0E2/ATP6V1C2/ATP6V0D1/TCIRG1/ATP6V1B2/ATP6V1E1/ATP6V1G1	7
group_G5_2_1	hsa04721	Synaptic vesicle cycle	7/12	78/8158	4.23147100883351e-12	1.48101485309173e-11	2.22709000464922e-12	ATP6V0E2/ATP6V1C2/ATP6V0D1/TCIRG1/ATP6V1B2/ATP6V1E1/ATP6V1G1	7
group_G5_2_1	hsa04150	mTOR signaling pathway	8/12	156/8158	6.93309717749965e-12	1.9412672096999e-11	2.9191988115788e-12	SLC38A9/STRADA/MIOS/LAMTOR2/ATP6V1C2/ATP6V1B2/ATP6V1E1/ATP6V1G1	8
group_G5_2_1	hsa05323	Rheumatoid arthritis	7/12	93/8158	1.50510077332097e-11	3.51190180441559e-11	5.28105534498585e-12	ATP6V0E2/ATP6V1C2/ATP6V0D1/TCIRG1/ATP6V1B2/ATP6V1E1/ATP6V1G1	7
group_G5_2_1	hsa00190	Oxidative phosphorylation	7/12	134/8158	2.03939290566566e-10	4.07878581133132e-10	6.13351249824259e-11	ATP6V0E2/ATP6V1C2/ATP6V0D1/TCIRG1/ATP6V1B2/ATP6V1E1/ATP6V1G1	7
group_G5_2_1	hsa04145	Phagosome	7/12	152/8158	4.97429185769114e-10	8.7050107509595e-10	1.30902417307662e-10	ATP6V0E2/ATP6V1C2/ATP6V0D1/TCIRG1/ATP6V1B2/ATP6V1E1/ATP6V1G1	7
group_G5_2_1	hsa05165	Human papillomavirus infection	7/12	331/8158	1.12984879508709e-07	1.75754257013547e-07	2.64292115809845e-08	ATP6V0E2/ATP6V1C2/ATP6V0D1/TCIRG1/ATP6V1B2/ATP6V1E1/ATP6V1G1	7
group_G5_2_3	hsa04142	Lysosome	5/7	132/8158	2.10413769137496e-08	1.05206884568748e-07	NA	CTNS/SGSH/MFSD8/NPC2/GNS	5
group_G5_2_3	hsa00531	Glycosaminoglycan degradation	2/7	19/8158	0.000107179622352766	0.000267949055881915	NA	SGSH/GNS	2
group_G5_3_1	hsa04142	Lysosome	10/10	132/8158	8.72085064834956e-19	1.22091909076894e-17	7.3438742301891e-18	GUSB/TPP1/HGSNAT/SLC17A5/PPT1/MANBA/NPC2/SMPD1/AGA/FUCA1	10
group_G5_3_1	hsa00511	Other glycan degradation	3/10	18/8158	1.07209797188726e-06	7.50468580321083e-06	4.51409672373584e-06	MANBA/AGA/FUCA1	3
group_G5_3_1	hsa00531	Glycosaminoglycan degradation	2/10	19/8158	0.000228714990395767	0.00106733662184691	0.000642006990584609	GUSB/HGSNAT	2
group_G5_3_2	hsa05110	Vibrio cholerae infection	6/7	50/8158	2.70929437071181e-13	3.52208268192535e-12	5.70377762255118e-13	ATP6V1B2/ATP6V1C1/ATP6V0B/ATP6V0A1/ATP6V1G2/ATP6V0C	6
group_G5_3_2	hsa05120	Epithelial cell signaling in Helicobacter pylori infection	6/7	70/8158	2.23074698000952e-12	1.44998553700619e-11	2.3481547157995e-12	ATP6V1B2/ATP6V1C1/ATP6V0B/ATP6V0A1/ATP6V1G2/ATP6V0C	6
group_G5_3_2	hsa04721	Synaptic vesicle cycle	6/7	78/8158	4.3662539998795e-12	1.82380079242102e-11	2.95352355047939e-12	ATP6V1B2/ATP6V1C1/ATP6V0B/ATP6V0A1/ATP6V1G2/ATP6V0C	6
group_G5_3_2	hsa04966	Collecting duct acid secretion	5/7	27/8158	5.61169474591084e-12	1.82380079242102e-11	2.95352355047939e-12	ATP6V1B2/ATP6V1C1/ATP6V0A1/ATP6V1G2/ATP6V0C	5
group_G5_3_2	hsa05323	Rheumatoid arthritis	6/7	93/8158	1.29369189265255e-11	3.36359892089663e-11	5.44712375853706e-12	ATP6V1B2/ATP6V1C1/ATP6V0B/ATP6V0A1/ATP6V1G2/ATP6V0C	6
group_G5_3_2	hsa00190	Oxidative phosphorylation	6/7	134/8158	1.212954752948e-10	2.62806863138733e-10	4.25598158929122e-11	ATP6V1B2/ATP6V1C1/ATP6V0B/ATP6V0A1/ATP6V1G2/ATP6V0C	6
group_G5_3_2	hsa04145	Phagosome	6/7	152/8158	2.61428553775019e-10	4.85510171296464e-10	7.86251289548930e-11	ATP6V1B2/ATP6V1C1/ATP6V0B/ATP6V0A1/ATP6V1G2/ATP6V0C	6
group_G5_3_2	hsa05165	Human papillomavirus infection	6/7	331/8158	2.88716293533618e-08	4.69163976992129e-08	7.59779719825311e-09	ATP6V1B2/ATP6V1C1/ATP6V0B/ATP6V0A1/ATP6V1G2/ATP6V0C	6
group_G5_3_2	hsa04150	mTOR signaling pathway	4/7	156/8158	4.30680745608633e-06	6.22094410323581e-06	1.00744034060499e-06	ATP6V1B2/ATP6V1C1/ATP6V1G2/SEH1L	4
group_G5_3_2	hsa04142	Lysosome	3/7	132/8158	0.000138214741377824	0.000179679163791172	2.90978402900683e-05	ATP6V0B/ATP6V0A1/ATP6V0C	3
group_G5_3_2	hsa05152	Tuberculosis	3/7	180/8158	0.000346381429141447	0.000409359870803528	6.62930964864014e-05	ATP6V0B/ATP6V0A1/ATP6V0C	3
group_G5_3_5	hsa04142	Lysosome	2/3	132/8158	0.000771281220591194	0.00231384366177358	NA	CTSE/CTSO	2
group_G5_4_1	hsa04150	mTOR signaling pathway	9/14	156/8158	5.00745092400594e-13	1.55230978644184e-11	1.00149018480119e-11	CAB39/TELO2/WDR24/FNIP1/ATP6V1C2/ATP6V1G3/LAMTOR4/NPRL3/RRAGC	9
group_G5_4_1	hsa05110	Vibrio cholerae infection	5/14	50/8158	1.35308028852631e-08	2.09727444721578e-07	1.35308028852631e-07	ATP6V1C2/ATP6V1G3/TCIRG1/ATP6V0B/ATP6V0A1	5
group_G5_4_1	hsa05120	Epithelial cell signaling in Helicobacter pylori infection	5/14	70/8158	7.58764600014064e-08	7.21767397212423e-07	4.65656385298337e-07	ATP6V1C2/ATP6V1G3/TCIRG1/ATP6V0B/ATP6V0A1	5
group_G5_4_1	hsa04966	Collecting duct acid secretion	4/14	27/8158	9.31312770596674e-08	7.21767397212423e-07	4.65656385298337e-07	ATP6V1C2/ATP6V1G3/TCIRG1/ATP6V0A1	4
group_G5_4_1	hsa04721	Synaptic vesicle cycle	5/14	78/8158	1.31373972851158e-07	8.1451863167718e-07	5.25495891404632e-07	ATP6V1C2/ATP6V1G3/TCIRG1/ATP6V0B/ATP6V0A1	5
group_G5_4_1	hsa05323	Rheumatoid arthritis	5/14	93/8158	3.18954564027154e-07	1.6479319141403e-06	1.06318188009051e-06	ATP6V1C2/ATP6V1G3/TCIRG1/ATP6V0B/ATP6V0A1	5
group_G5_4_1	hsa00190	Oxidative phosphorylation	5/14	134/8158	1.97243110956768e-06	8.73505205665685e-06	5.63551745590765e-06	ATP6V1C2/ATP6V1G3/TCIRG1/ATP6V0B/ATP6V0A1	5
group_G5_4_1	hsa04145	Phagosome	5/14	152/8158	3.6757325392122e-06	1.42434635894473e-05	9.1893313480305e-06	ATP6V1C2/ATP6V1G3/TCIRG1/ATP6V0B/ATP6V0A1	5
group_G5_4_1	hsa05165	Human papillomavirus infection	5/14	331/8158	0.000157783422903167	0.000543476234444242	0.000350629828673704	ATP6V1C2/ATP6V1G3/TCIRG1/ATP6V0B/ATP6V0A1	5
group_G5_4_1	hsa04142	Lysosome	3/14	132/8158	0.0013227773151566	0.00410060967698546	0.0026455546303132	TCIRG1/ATP6V0B/ATP6V0A1	3
group_G5_4_1	hsa05152	Tuberculosis	3/14	180/8158	0.00321405190340156	0.00905778263685895	0.00584373073345739	TCIRG1/ATP6V0B/ATP6V0A1	3
group_G5_4_2	hsa04150	mTOR signaling pathway	3/4	156/8158	2.70577210814805e-05	0.00278694527139249	0.00176587232321241	CASTOR2/PIK3R1/GRB10	3
group_G5_4_6	hsa00531	Glycosaminoglycan degradation	2/3	19/8158	1.53967584055772e-05	0.000215554617678081	0.000145864027000205	HYAL1/ARSB	2
group_G5_4_6	hsa04142	Lysosome	2/3	132/8158	0.000771281220591194	0.00539896854413836	0.00365343736069513	HYAL1/ARSB	2
group_G5_5_0	hsa04137	Mitophagy - animal	10/39	72/8158	7.78844876112942e-13	1.46422836709233e-10	8.85423648633660e-11	BECN1/E2F1/USP30/CALCOCO2/MAP1LC3B/SP1/AMBRA1/FUNDC1/MAP1LC3B2/FOXO3	10
group_G5_5_0	hsa04140	Autophagy - animal	11/39	141/8158	3.07774770519514e-11	2.89308284288343e-09	1.74945659032145e-09	BECN1/RHEB/RPS6KB2/ATG10/PRKACA/PIK3R2/MAP1LC3B/AKT1S1/AMBRA1/MAP1LC3B2/RPTOR	11
group_G5_5_0	hsa04211	Longevity regulating pathway	9/39	89/8158	2.35033962937434e-10	1.47287950107459e-08	8.90655017447119e-09	PPARGC1A/RHEB/RPS6KB2/PRKACA/SESN2/PIK3R2/AKT1S1/FOXO3/RPTOR	9
group_G5_5_0	hsa05131	Shigellosis	12/39	247/8158	8.60970616658588e-10	4.04656189829537e-08	2.44696912102967e-08	TLR4/BECN1/RPS6KB2/PXN/PIK3R2/CALCOCO2/MAP1LC3B/MAPK14/AKT1S1/MAP1LC3B2/FOXO3/RPTOR	12
group_G5_5_0	hsa01522	Endocrine resistance	7/39	98/8158	3.26653377077268e-07	1.22821669781053e-05	7.42706625775683e-06	E2F1/RPS6KB2/PRKACA/PIK3R2/MAPK14/SP1/ESR1	7
group_G5_5_0	hsa04213	Longevity regulating pathway - multiple species	6/39	62/8158	4.03904968252445e-07	1.26556890052433e-05	7.65293624057264e-06	RPS6KB2/PRKACA/PIK3R2/AKT1S1/FOXO3/RPTOR	6
group_G5_5_0	hsa04152	AMPK signaling pathway	7/39	120/8158	1.30166930242635e-06	3.49591184080219e-05	2.11398924303828e-05	PPARGC1A/RHEB/RPS6KB2/PIK3R2/AKT1S1/FOXO3/RPTOR	7
group_G5_5_0	hsa04910	Insulin signaling pathway	7/39	137/8158	3.17302970553271e-06	7.45661980800186e-05	4.50904221312543e-05	PPARGC1A/RHOQ/RHEB/RPS6KB2/PRKACA/PIK3R2/RPTOR	7
group_G5_5_0	hsa04150	mTOR signaling pathway	7/39	156/8158	7.51730846397593e-06	0.000157028221247497	9.49554753344328e-05	RHEB/RPS6KB2/SESN2/PIK3R2/AKT1S1/WDR59/RPTOR	7
group_G5_5_0	hsa05163	Human cytomegalovirus infection	8/39	225/8158	8.69379807068949e-06	0.000163443403728962	9.88347570141543e-05	E2F1/RHEB/RPS6KB2/PRKACA/PXN/PIK3R2/MAPK14/SP1	8
group_G5_5_0	hsa05205	Proteoglycans in cancer	7/39	205/8158	4.43532060748647e-05	0.000706712277643692	0.000427351209325413	TLR4/RPS6KB2/PRKACA/PXN/PIK3R2/MAPK14/ESR1	7
group_G5_5_0	hsa04371	Apelin signaling pathway	6/39	139/8158	4.51092943176825e-05	0.000706712277643692	0.000427351209325413	PPARGC1A/BECN1/RPS6KB2/PRKACA/MAP1LC3B/MAP1LC3B2	6
group_G5_5_0	hsa04714	Thermogenesis	7/39	232/8158	9.71794987697135e-05	0.00140536505913124	0.000849828815152151	PPARGC1A/RHEB/RPS6KB2/PRKACA/MAPK14/AKT1S1/RPTOR	7
group_G5_5_0	hsa05014	Amyotrophic lateral sclerosis	8/39	364/8158	0.000265088864376341	0.00355826413918621	0.00215169388035896	BECN1/XBP1/RAB5A/MAP1LC3B/MAPK14/AMBRA1/HDAC6/MAP1LC3B2	8
group_G5_5_0	hsa05167	Kaposi sarcoma-associated herpesvirus infection	6/39	194/8158	0.000283904053658474	0.00355826413918621	0.00215169388035896	BECN1/E2F1/PIK3R2/MAP1LC3B/MAPK14/MAP1LC3B2	6
group_G5_5_0	hsa04917	Prolactin signaling pathway	4/39	70/8158	0.000325989940277846	0.00383038179826469	0.00231624431250048	PIK3R2/MAPK14/FOXO3/ESR1	4
group_G5_5_0	hsa04136	Autophagy - other	3/39	32/8158	0.000455245880963775	0.00477359322467564	0.00288660732511181	BECN1/ATG10/RPTOR	3
group_G5_5_0	hsa05170	Human immunodeficiency virus 1 infection	6/39	212/8158	0.00045704615980937	0.00477359322467564	0.00288660732511181	TLR4/CUL4A/RPS6KB2/PXN/PIK3R2/MAPK14	6
group_G5_5_0	hsa04936	Alcoholic liver disease	5/39	142/8158	0.000532407951323339	0.00516794454120917	0.00312507284686781	PPARGC1A/TLR4/MAPK14/NOX4/FOXO3	5
group_G5_5_0	hsa05017	Spinocerebellar ataxia	5/39	143/8158	0.000549781334171188	0.00516794454120917	0.00312507284686781	BECN1/XBP1/PIK3R2/SP1/AMBRA1	5
group_G5_5_0	hsa05224	Breast cancer	5/39	147/8158	0.000623583421744106	0.00558255634704247	0.00337578995229892	E2F1/RPS6KB2/PIK3R2/SP1/ESR1	5
group_G5_5_0	hsa05235	PD-L1 expression and PD-1 checkpoint pathway in cancer	4/39	89/8158	0.000813357108344704	0.00667571392968221	0.00403682589252899	TLR4/RPS6KB2/PIK3R2/MAPK14	4
group_G5_5_0	hsa04218	Cellular senescence	5/39	156/8158	0.000816709682886653	0.00667571392968221	0.00403682589252899	E2F1/RHEB/PIK3R2/MAPK14/FOXO3	5
group_G5_5_0	hsa05231	Choline metabolism in cancer	4/39	98/8158	0.00116680136928546	0.00913994405940281	0.0055269538545101	RHEB/RPS6KB2/PIK3R2/SP1	4
group_G5_5_1	hsa05110	Vibrio cholerae infection	5/8	50/8158	3.89097703455596e-10	5.83646555183395e-09	1.22872958985978e-09	ATP6V1H/ATP6V0A2/ATP6V1D/ATP6V1B1/ATP6V0E1	5
group_G5_5_1	hsa05120	Epithelial cell signaling in Helicobacter pylori infection	5/8	70/8158	2.20898397343677e-09	1.65673798007758e-08	3.48786943174226e-09	ATP6V1H/ATP6V0A2/ATP6V1D/ATP6V1B1/ATP6V0E1	5
group_G5_5_1	hsa04721	Synaptic vesicle cycle	5/8	78/8158	3.84359025887776e-09	1.92179512943888e-08	4.04588448302922e-09	ATP6V1H/ATP6V0A2/ATP6V1D/ATP6V1B1/ATP6V0E1	5
group_G5_5_1	hsa04966	Collecting duct acid secretion	4/8	27/8158	6.60155935647541e-09	2.47558475867828e-08	5.21175738669112e-09	ATP6V0A2/ATP6V1D/ATP6V1B1/ATP6V0E1	4
group_G5_5_1	hsa05323	Rheumatoid arthritis	5/8	93/8158	9.41838612318623e-09	2.82551583695587e-08	5.94845439359131e-09	ATP6V1H/ATP6V0A2/ATP6V1D/ATP6V1B1/ATP6V0E1	5
group_G5_5_1	hsa00190	Oxidative phosphorylation	5/8	134/8158	5.9739091058323e-08	1.49347727645808e-07	3.14416268728016e-08	ATP6V1H/ATP6V0A2/ATP6V1D/ATP6V1B1/ATP6V0E1	5
group_G5_5_1	hsa04145	Phagosome	5/8	152/8158	1.12575471225408e-07	2.41233152625875e-07	5.07859268686052e-08	ATP6V1H/ATP6V0A2/ATP6V1D/ATP6V1B1/ATP6V0E1	5
group_G5_5_1	hsa05165	Human papillomavirus infection	5/8	331/8158	5.40315977943836e-06	1.01309245864469e-05	2.13282622872567e-06	ATP6V1H/ATP6V0A2/ATP6V1D/ATP6V1B1/ATP6V0E1	5
group_G5_5_1	hsa04150	mTOR signaling pathway	3/8	156/8158	0.000357976679027342	0.000596627798378904	0.000125605852290296	ATP6V1H/ATP6V1D/ATP6V1B1	3
group_G5_5_2	hsa04142	Lysosome	4/7	132/8158	2.20786513796839e-06	4.41573027593679e-05	1.16203428314126e-05	CTSA/HEXB/NAGA/LIPA	4
group_G5_5_2	hsa00603	Glycosphingolipid biosynthesis - globo and isoglobo series	2/7	15/8158	6.59198113496788e-05	0.000659198113496788	0.000173473187762313	HEXB/NAGA	2
group_G5_5_3	hsa04150	mTOR signaling pathway	5/7	156/8158	4.88469317603976e-08	9.76938635207952e-07	9.2552081230227e-07	LAMTOR5/SLC38A9/TTI1/DEPDC5/RRAGD	5
group_G5_6_0	hsa04140	Autophagy - animal	17/43	141/8158	1.17892162348869e-19	1.94522067875634e-17	1.12928281828917e-17	SH3GLB1/HIF1A/CAMKK2/DAPK1/RPS6KB1/ULK1/RAB7A/PIK3R4/PIK3C3/KRAS/GABARAPL2/MAPK8/AKT1S1/RAB8A/ATG16L2/RRAGB/ATG14	17
group_G5_6_0	hsa04137	Mitophagy - animal	10/43	72/8158	2.28447989756752e-12	1.8846959154932e-10	1.09414563515076e-10	HIF1A/OPTN/BNIP3L/ULK1/USP8/RAB7A/KRAS/GABARAPL2/MAPK8/ATF4	10
group_G5_6_0	hsa04211	Longevity regulating pathway	8/43	89/8158	1.5481804516264e-08	8.51499248394522e-07	4.94331302098256e-07	CAMKK2/RPS6KB1/ULK1/SESN1/PRKAB1/KRAS/AKT1S1/ATF4	8
group_G5_6_0	hsa04150	mTOR signaling pathway	8/43	156/8158	1.22758650039336e-06	5.06379431412259e-05	2.93974661936304e-05	LAMTOR1/RPS6KB1/SEC13/ULK1/KRAS/AKT1S1/FLCN/RRAGB	8
group_G5_6_0	hsa04068	FoxO signaling pathway	7/43	131/8158	4.66887778231376e-06	0.000154072966816354	8.94458690927478e-05	EGF/PRKAB1/KRAS/GABARAPL2/MAPK8/STAT3/FOXO4	7
group_G5_6_0	hsa04371	Apelin signaling pathway	7/43	139/8158	6.91877650597046e-06	0.000190266353914188	0.000110457660007599	EGR1/RPS6KB1/PRKAB1/PIK3R4/PIK3C3/KRAS/HDAC5	7
group_G5_6_0	hsa04213	Longevity regulating pathway - multiple species	5/43	62/8158	1.65920145766256e-05	0.000391097486449033	0.000227048620522246	RPS6KB1/PRKAB1/KRAS/AKT1S1/HSPA1A	5
group_G5_6_0	hsa04152	AMPK signaling pathway	6/43	120/8158	3.49213785378232e-05	0.000669105348490183	0.000388443934370696	CAMKK2/RPS6KB1/ULK1/PRKAB1/AKT1S1/RAB8A	6
group_G5_6_0	hsa05131	Shigellosis	8/43	247/8158	3.64966553721918e-05	0.000669105348490183	0.000388443934370696	RPS6KB1/PIK3R4/PIK3C3/MAPK8/AKT1S1/FOXO4/RRAGB/ATG14	8
group_G5_6_0	hsa04144	Endocytosis	8/43	251/8158	4.09384356062428e-05	0.00067290492238741	0.000390649747606088	SH3GLB1/USP8/SMURF1/RAB7A/RAB5A/NEDD4/RAB8A/HSPA1A	8
group_G5_6_0	hsa05212	Pancreatic cancer	5/43	76/8158	4.48603281591607e-05	0.00067290492238741	0.000390649747606088	EGF/RPS6KB1/KRAS/MAPK8/STAT3	5
group_G5_6_0	hsa05014	Amyotrophic lateral sclerosis	9/43	364/8158	9.29422900681766e-05	0.00121618093015296	0.000706044431540155	OPTN/SEC13/ULK1/RAB5A/PIK3R4/PIK3C3/RAB8A/ATF4/ATG14	9
group_G5_6_0	hsa05235	PD-L1 expression and PD-1 checkpoint pathway in cancer	5/43	89/8158	9.5820315709021e-05	0.00121618093015296	0.000706044431540155	HIF1A/EGF/RPS6KB1/KRAS/STAT3	5
group_G5_6_0	hsa05022	Pathways of neurodegeneration - multiple diseases	10/43	476/8158	0.000139199677094754	0.00164056762290246	0.000952418843279897	OPTN/ULK1/RAB5A/PIK3R4/PIK3C3/KRAS/MAPK8/RAB8A/ATF4/ATG14	10
group_G5_6_0	hsa05231	Choline metabolism in cancer	5/43	98/8158	0.000151381909241814	0.00166520100165995	0.000966719560772285	HIF1A/EGF/RPS6KB1/KRAS/MAPK8	5
group_G5_6_0	hsa04920	Adipocytokine signaling pathway	4/43	69/8158	0.000451134052390345	0.00465231991527543	0.00270086833996851	CAMKK2/PRKAB1/MAPK8/STAT3	4
group_G5_6_0	hsa05167	Kaposi sarcoma-associated herpesvirus infection	6/43	194/8158	0.000490246999299386	0.00475827969908228	0.00276238247283245	HIF1A/PIK3C3/KRAS/MAPK8/STAT3/ATG14	6
group_G5_6_0	hsa04136	Autophagy - other	3/43	32/8158	0.000608237039543664	0.00557550619581692	0.00323681699406277	PIK3R4/PIK3C3/GABARAPL2	3
group_G5_6_0	hsa01521	EGFR tyrosine kinase inhibitor resistance	4/43	79/8158	0.00075471069067243	0.00655406652426058	0.00380491262333469	EGF/RPS6KB1/KRAS/STAT3	4
group_G5_6_0	hsa05017	Spinocerebellar ataxia	5/43	143/8158	0.000868975740111364	0.00716904985591876	0.00416193643948074	ULK1/PIK3R4/PIK3C3/MAPK8/ATG14	5
group_G5_6_0	hsa04012	ErbB signaling pathway	4/43	85/8158	0.000994044521975792	0.00778925032637766	0.0045219890252017	EGF/RPS6KB1/KRAS/MAPK8	4
group_G5_6_0	hsa05210	Colorectal cancer	4/43	86/8158	0.00103856671018369	0.00778925032637766	0.0045219890252017	EGF/RPS6KB1/KRAS/MAPK8	4
group_G5_6_0	hsa05219	Bladder cancer	3/43	41/8158	0.00126478274103901	0.00907344140310593	0.00526751622126086	EGF/DAPK1/KRAS	3
group_G5_6_0	hsa04912	GnRH signaling pathway	4/43	93/8158	0.00139035451886937	0.00955868731722695	0.00554922198320672	EGR1/KRAS/MAPK8/ATF4	4
group_G5_6_1	hsa04966	Collecting duct acid secretion	7/8	27/8158	1.48952251679287e-17	1.78742702015145e-16	1.56791843872934e-17	ATP6V0E2/ATP6V0A2/ATP6V1E1/ATP6V1G2/ATP6V0E1/ATP6V0A4/ATP6V1A	7
group_G5_6_1	hsa05110	Vibrio cholerae infection	7/8	50/8158	1.67124907072468e-15	1.00274944243481e-14	8.79604774065618e-16	ATP6V0E2/ATP6V0A2/ATP6V1E1/ATP6V1G2/ATP6V0E1/ATP6V0A4/ATP6V1A	7
group_G5_6_1	hsa05120	Epithelial cell signaling in Helicobacter pylori infection	7/8	70/8158	2.00144349717054e-14	8.00577398868218e-14	7.02260876200191e-15	ATP6V0E2/ATP6V0A2/ATP6V1E1/ATP6V1G2/ATP6V0E1/ATP6V0A4/ATP6V1A	7
group_G5_6_1	hsa04721	Synaptic vesicle cycle	7/8	78/8158	4.40703816618938e-14	1.32211144985681e-13	1.15974688583931e-14	ATP6V0E2/ATP6V0A2/ATP6V1E1/ATP6V1G2/ATP6V0E1/ATP6V0A4/ATP6V1A	7
group_G5_6_1	hsa05323	Rheumatoid arthritis	7/8	93/8158	1.5777598595526e-13	3.78662366292623e-13	3.32159970432126e-14	ATP6V0E2/ATP6V0A2/ATP6V1E1/ATP6V1G2/ATP6V0E1/ATP6V0A4/ATP6V1A	7
group_G5_6_1	hsa00190	Oxidative phosphorylation	7/8	134/8158	2.1762331559489e-12	4.35246631189781e-12	3.81795290517352e-13	ATP6V0E2/ATP6V0A2/ATP6V1E1/ATP6V1G2/ATP6V0E1/ATP6V0A4/ATP6V1A	7
group_G5_6_1	hsa04145	Phagosome	7/8	152/8158	5.34981891344821e-12	9.17111813733978e-12	8.04484047135068e-13	ATP6V0E2/ATP6V0A2/ATP6V1E1/ATP6V1G2/ATP6V0E1/ATP6V0A4/ATP6V1A	7
group_G5_6_1	hsa05165	Human papillomavirus infection	7/8	331/8158	1.31464522476842e-09	1.97196783715262e-09	1.72979634837949e-10	ATP6V0E2/ATP6V0A2/ATP6V1E1/ATP6V1G2/ATP6V0E1/ATP6V0A4/ATP6V1A	7
group_G5_6_1	hsa04150	mTOR signaling pathway	3/8	156/8158	0.000357976679027342	0.000477302238703123	4.18686174300985e-05	ATP6V1E1/ATP6V1G2/ATP6V1A	3
group_G5_6_1	hsa04142	Lysosome	2/8	132/8158	0.00682558023927481	0.00819069628712978	0.00071848213044998	ATP6V0A2/ATP6V0A4	2
group_G5_6_2	hsa04142	Lysosome	6/6	132/8158	1.60209581095825e-11	1.2816766487666e-10	NA	PPT2/IDS/ARSG/NAGLU/GALNS/GLA	6
group_G5_6_2	hsa00531	Glycosaminoglycan degradation	3/6	19/8158	2.13302060785181e-07	8.53208243140725e-07	NA	IDS/NAGLU/GALNS	3
group_G5_6_4	hsa03460	Fanconi anemia pathway	1/1	54/8158	0.00661926942878177	0.00661926942878177	NA	WDR48	1
group_G9_0	hsa04210	Apoptosis	2/2	136/8158	0.000275904328280708	0.000943800181790296	NA	AIFM1/PARP1	2
group_G9_0	hsa04217	Necroptosis	2/2	159/8158	0.000377520072716118	0.000943800181790296	NA	AIFM1/PARP1	2
group_G9_All	hsa04210	Apoptosis	2/3	136/8158	0.000818646976997686	0.00391309090575625	0.000588434722670112	PARP1/AIFM1	2
group_G9_All	hsa04217	Necroptosis	2/3	159/8158	0.00111802597307321	0.00391309090575625	0.000588434722670112	PARP1/AIFM1	2
